Abstract Number: 1729 • 2019 ACR/ARP Annual Meeting
Infections and Mortality in 230 Childhood Lupus Patients: A Single Center Experience from North India
Background/Purpose: Children with systemic lupus erythematosus(cSLE) have more severe disease as compared to adults. Additionally, Asians in their geographic area have high burden of infections…Abstract Number: 1754 • 2019 ACR/ARP Annual Meeting
Comorbidities and Treatments in United States Youth with Chronic Musculoskeletal Pain
Background/Purpose: Chronic musculoskeletal (MSK) pain has been associated with chronic illnesses, including mental disorders, and with high rates of pain medication use, often in referral…Abstract Number: 2296 • 2017 ACR/ARHP Annual Meeting
Infliximab Use in JIA and Uveitis: Does Methotrexate Help or Hinder?
Background/Purpose: Infliximab (IFX) effectiveness is impacted in part by immunogenicity and the development of drug neutralizing anti-drug antibodies, thus methotrexate is commonly co-administered to minimize…Abstract Number: 2997 • 2017 ACR/ARHP Annual Meeting
Patient and Family Reported Psychosocial Areas of Concern within Pediatric Rheumatology: Quality Improvement Data and Implications for Practice
Background/Purpose: Psychosocial factors greatly impact the subjective disease experience and outcomes of children with rheumatic conditions. Attention to the psychosocial aspects of patients’ needs is…Abstract Number: 42 • 2017 Pediatric Rheumatology Symposium
Evaluation of a Dosing Regimen for Tocilizumab in Patients Younger Than Two Years of Age With Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of systemic juvenile idiopathic arthritis (sJIA) based on clinical trials in patients ≥2 years of age. This…Abstract Number: 100 • 2017 Pediatric Rheumatology Symposium
Improvement of Salivary Gland Ultrasound Findings in Juvenile Sjögren’s Syndrome after Systemic Corticosteroid Treatment
Background/Purpose: Juvenile Sjögren’sSyndrome (jSS) is a rare systemic autoimmune disease affecting predominantly salivary glands (SG) in children who do not meet criteria for SLE or MCTD. Currently, no specific criteria for…Abstract Number: 1391 • 2016 ACR/ARHP Annual Meeting
Novel Electronic Health Record-Based Method Confirms Increased Renal Disease Burden in Pediatric-Onset Vs. Adult-Onset Patients with Systemic Lupus Erythematosus
Background/Purpose: Children with Systemic Lupus Erythematosus (SLE) are often understudied compared with adults. Using the electronic health record (EHR) can increase sample size and the…Abstract Number: 1399 • 2016 ACR/ARHP Annual Meeting
Transitioning Lupus Patients from Pediatric to Adult Rheumatology
Background/Purpose: Pediatric rheumatologists have successfully improved the life expectancy and quality of life of children with systemic lupus (cSLE). cSLE has higher morbidity and mortality…Abstract Number: 3267 • 2015 ACR/ARHP Annual Meeting
Functional Disability in Adolescents Is Predicted By Self-Report of Sleep Problems, Depressive Symptoms, Low Physical Activity and Worst Pain Intensity Levels
Background/Purpose: Pain intensity has been shown to be important in understanding pain related functional disability in adolescents. Additional factors may affect other critical outcomes including…Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…Abstract Number: 2457 • 2015 ACR/ARHP Annual Meeting
Physical Function and Psychological Well-Being in Teens with Juvenile Idiopathic Arthritis (JIA): Characterization and Exploration of Technology-Assisted Self-Management
Background/Purpose: This study sought to assess the physical function and psychological well- being of teens with juvenile idiopathic arthritis (JIA) as well as to assess…Abstract Number: 2456 • 2015 ACR/ARHP Annual Meeting
Anti SRP+Ve Myositis in Childhood. Presentation and Physiotherapy Treatment of This Rare Childhood Myositis
Background/Purpose: Previously it was understood that all Myositis in childhood was Juvenile Dermatomyositis. More recently Myositis specific antibodies have been discovered and these appear to…Abstract Number: 2416 • 2015 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Six to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of adult patients with rheumatoid arthritis (RA). We report the pharmacokinetics (PK), safety and…Abstract Number: 2164 • 2013 ACR/ARHP Annual Meeting
Rituximab In The Treatment Of Children With Systemic LUPUS Erythematosus: ONE Year Analysis Of 12 Patients
Background/Purpose: Treatment of childhood systemic lupus erythematosus (SLE) is an ongoing problem because of the severity of the disease in some patients and the side-effects…Abstract Number: 303 • 2012 ACR/ARHP Annual Meeting
Ancestral Group Differences in Pediatric SLE Early Disease Severity: An Analysis of the Carranet Registry
Background/Purpose: Ancestral background may contribute to increased disease morbidity in patients with pediatric lupus systemic erythematosus (pSLE) of non-European descent; however, there exists a paucity…
ACR Meeting Abstracts